Sign In
Buy ARTL
$0.770
+0.0148 (+1.96%)
At Close: Jul 31, 2026
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
08:30am, Tuesday, 04'th Nov 2025
SOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treat
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
08:00am, Monday, 27'th Oct 2025
SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treat
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Up 64.3% in September
02:54am, Friday, 24'th Oct 2025
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) was the recipient of a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 6
Artelo Biosciences, Inc. (NASDAQ:ARTL) Receives Average Rating of “Hold” from Brokerages
01:56am, Thursday, 23'rd Oct 2025
Shares of Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) have earned an average rating of "Hold" from the five analysts that are covering the stock, Marketbeat.com reports. One research ana
ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial
Artelo Biosciences Announces Closing of $2.0 Million Public Offering
04:05pm, Wednesday, 01'st Oct 2025
SOLANA BEACH, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop t
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
08:30am, Tuesday, 30'th Sep 2025
SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop
Artelo Biosciences Announces Proposed Underwritten Public Offering
07:15pm, Monday, 29'th Sep 2025
SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop
Patients treated with ART27.13 showed consistent improvements in weight, lean body mass, and activity While clinical benefits were observed in all treated cohorts, the best outcomes in CAReS were obse
Artelo Biosciences Announces Closing of $3.0 Million Public Offering
04:05pm, Friday, 05'th Sep 2025
SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
08:37am, Thursday, 04'th Sep 2025
SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop
Artelo Biosciences Announces Proposed Underwritten Public Offering
04:35pm, Wednesday, 03'rd Sep 2025
SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop
Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results
11:33am, Wednesday, 03'rd Sep 2025
SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)
08:45am, Wednesday, 03'rd Sep 2025
Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACS Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Ac
Safety and Pharmacokinetic Data Support Dosing of ART26.12 in Fed or Fasted Conditions Completion of Positive Single Ascending Dose Study with a Preliminary Food Effect Assessment Advances ART26.12 To
